Market LIVE
Published markets; coverage varies by country
Product profile · United States

DAPTOMYCIN

 ·  Patent Litigation & Settlement History ↓

IngredientDAPTOMYCIN
Application typeNDA
Application209949
Product001
Dosage formPOWDER
RouteINTRAVENOUS
Strength350MG/VIAL
Approval date2017-10-20
Marketing statusPrescription
Status event—
ApplicantHIKMA PHARMS
Product source

Current GenericRadar decision

Year2017
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeAPPROVAL_DATE
Anchor date2017-10-20
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

APPROVAL_YEAR_FALLBACK: current product-specific evidence does not establish a DS/DS-equivalent or all-indication exclusivity anchor. Evidence limits: complete comparison of unverified ANDA candidates against original RLD documents remains incomplete; absence of generics is not established; complete historical patent/exclusivity collection remains incomplete.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
212667 / 001FINAL_APPROVAL · FINAL_APPROVED2019-07-12—ACCORD HEALTHCARE INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213425 / 001FINAL_APPROVAL · FINAL_APPROVED2020-08-20—BE PHARMACEUTICALS AGNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211403 / 001FINAL_APPROVAL · FINAL_APPROVED2020-08-31—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213786 / 001FINAL_APPROVAL · FINAL_APPROVED2021-06-29—MEITHEAL PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216445 / 001FINAL_APPROVAL · FINAL_APPROVED2022-12-23—ASPIRO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213396 / 001FINAL_APPROVAL · FINAL_APPROVED2024-08-01—FRESENIUS KABI USA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 6 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
212667 / 001ACCORD HEALTHCARE INCFINAL_APPROVAL · FINAL_APPROVED2019-07-12 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213425 / 001BE PHARMACEUTICALS AGFINAL_APPROVAL · FINAL_APPROVED2020-08-20 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211403 / 001DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2020-08-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213786 / 001MEITHEAL PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-06-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216445 / 001ASPIRO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2022-12-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213396 / 001FRESENIUS KABI USA LLCFINAL_APPROVAL · FINAL_APPROVED2024-08-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.